Aspirin may improve the survival of COVID-19 patients suffering from postcochlear syndrome, the Journal of the American Medical Association writes. The clinical trial, called REMAP-CAP, funded by the NIHR in the United Kingdom enrolled 1,557 COVID-19 patients in critical condition from 105 hospitals in Canada, France, Germany, India, Italy, Nepal, the Netherlands and the United Kingdom. Some of these patients were given aspirin, others were given another type of antiplatelet drug called clopidogrel, and others were given no antiplatelet drugs. As it turns out, the use of antiplatelet drugs, such as aspirin, to treat critically ill patients with COVID-19 does not seem to reduce the need for life support and intensive care. However, people who received these drugs were more likely to survive the next 3 months (70.5% chance of survival compared with 67.3% in patients who did not receive antiplatelet drugs). People who have had severe COVID-19 are at risk of blood clots, which can block blood vessels and lead to potentially fatal organ damage.